Top

Molecular Imaging and Biology

Published in:

01-08-2011 | Research Article

Quantitating Antibody Uptake In Vivo: Conditional Dependence on Antigen Expression Levels

Authors: Greg M. Thurber, Ralph Weissleder

Published in: Molecular Imaging and Biology | Issue 4/2011

Abstract

Purpose

Antibodies form an important class of cancer therapeutics, and there is intense interest in using them for imaging applications in diagnosis and monitoring of cancer treatment. Despite the expanding body of knowledge describing pharmacokinetic and pharmacodynamic interactions of antibodies in vivo, discrepancies remain over the effect of antigen expression level on tumoral uptake with some reports indicating a relationship between uptake and expression and others showing no correlation.

Procedures

Using a cell line with high epithelial cell adhesion molecule expression and moderate epidermal growth factor receptor expression, fluorescent antibodies with similar plasma clearance were imaged in vivo. A mathematical model and mouse xenograft experiments were used to describe the effect of antigen expression on uptake of these high-affinity antibodies.

Results

As predicted by the theoretical model, under subsaturating conditions, uptake of the antibodies in such tumors is similar because localization of both probes is limited by delivery from the vasculature. In a separate experiment, when the tumor is saturated, the uptake becomes dependent on the number of available binding sites. In addition, targeting of small micrometastases is shown to be higher than larger vascularized tumors.

Conclusions

These results are consistent with the prediction that high affinity antibody uptake is dependent on antigen expression levels for saturating doses and delivery for subsaturating doses. It is imperative for any probe to understand whether quantitative uptake is a measure of biomarker expression or transport to the region of interest. The data provide support for a predictive theoretical model of antibody uptake, enabling it to be used as a starting point for the design of more efficacious therapies and timely quantitative imaging probes.

Available only for authorised users

Li WP, Meyer LA, Capretto DA, Sherman CD, Anderson CJ (2008) Receptor-binding, biodistribution, and metabolism studies of Cu-64-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Cancer Biother Radiopharm 23:158–171CrossRef

Zhao BS, Schwartz LH, Larson SM (2009) Imaging surrogates of tumor response to therapy: anatomic and functional biomarkers. J Nucl Med 50:239–249PubMedCrossRef

McLarty K, Cornelissen B, Cai ZL, Scollard DA, Costantini DL, Done SJ, Reilly RM (2009) Micro-SPECT/CT with In-111-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. J Nucl Med 50:1340–1348PubMedCrossRef

Zhang YJ, Xiang LM, Hassan R, Pastan I (2007) Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc Natl Acad Sci USA 104:17099–17104PubMedCrossRef

Wu AM, Senter PD (2005) Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 23:1137–1146PubMedCrossRef

Sharkey RM, Karacay H, Cardillo TM, Chang CH, McBride WJ, Rossi EA, Horak ID, Goldenberg DM (2005) Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res 11:7109S–7121SPubMedCrossRef

Mattes MJ, Sharkey RM, Karacay H, Czuczman MS, Goldenberg DM (2008) Therapy of advanced B-lymphoma xenografts with a combination of Y-90-anti-CD22 IgG (Epratuzumab) and unlabeled Anti-CD20 IgG (Veltuzumab). Clin Cancer Res 14:6154–6160PubMedCrossRef

Thurber G, Figueiredo J, Weissleder R (2009) Multicolor fluorescent intravital live microscopy (FILM) for surgical tumor resection in a mouse xenograft model. Plos One 4:e8053PubMedCrossRef

Zou P, Xu SB, Povoski SP, Wang A, Johnson MA, Martin EW, Subramaniam V, Xu R, Sun DX (2009) Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice. Mol Pharm 6:428–440PubMedCrossRef

10.

Urano Y, Asanuma D, Hama Y, Koyama Y, Barrett T, Kamiya M, Nagano T, Watanabe T, Hasegawa A, Choyke PL et al (2009) Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med 15:104–109PubMedCrossRef

11.

Rosenthal EL, Kulbersh BD, King T, Chaudhuri TR, Zinn KR (2007) Use of fluorescent labeled anti-epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts. Mol Cancer Ther 6:1230–1238PubMedCrossRef

12.

Jayson GC, Zweit J, Jackson A, Mulatero C, Julyan P, Ranson M, Broughton L, Wagstaff J, Hakannson L, Groenewegen G et al (2002) Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: Implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 94:1484–1493PubMed

13.

Stollman TH, Scheer MGW, Franssen GM, Verrijp KN, Oyen WJG, Ruers TJM, Leenders WPJ, Boerman OC (2009) Tumor Accumulation of radiolabeled bevacizumab due to targeting of cell- and matrix-associated VEGF-A isoforms. Cancer Biother Radiopharm 24:195–200PubMedCrossRef

14.

Wu AM, Olafsen T (2008) Antibodies for molecular imaging of cancer. Cancer J 14:191–197PubMedCrossRef

15.

Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM (2006) Early tumor response to Hsp90 therapy using HER2 PET: comparison with F-18-FDG PET. J Nucl Med 47:793–796PubMed

16.

Cai WB, Chen K, He LN, Cao QH, Koong A, Chen XY (2007) Quantitative PET of EGFR expression in xenograft-bearing mice using Cu-64-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 34:850–858PubMedCrossRef

17.

McLarty K, Cornelissen B, Scollard DA, Done SJ, Chun K, Reilly RM (2009) Associations between the uptake of In-111-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. Eur J Nucl Med Mol Imaging 36:81–93PubMedCrossRef

18.

Aerts H, Dubois L, Perk L, Vermaelen P, van Dongen G, Wouters BG, Lambin P (2009) Disparity between In vivo EGFR expression and Zr-89-labeled cetuximab uptake assessed with PET. J Nucl Med 50:123–131PubMedCrossRef

19.

Milenic DE, Wong KJ, Baidoo KE, Ray GL, Garmestani K, Williams M, Brechbiel MW (2008) Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. Cancer Biother Radiopharm 23:619–631PubMedCrossRef

20.

Niu G, Li Z, Xie J, Le Q-T, Chen X (2009) PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med 50:1116–1123PubMedCrossRef

21.

Thurber G, Schmidt M, Wittrup KD (2008) Factors determining antibody distribution in tumors. Trends Pharmacol Sci 29:57–61PubMed

22.

Thurber GM, Schmidt MM, Wittrup KD (2008) Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 60:1421–1434PubMedCrossRef

23.

Thurber GM, Wittrup KD (2008) Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids. Cancer Res 68:3334–3341PubMedCrossRef

24.

Thurber GM, Zajic SC, Wittrup KD (2007) Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med 48:995–999PubMedCrossRef

25.

Schmidt MM, Wittrup KD (2009) A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 8:2861PubMedCrossRef

26.

Mager DE (2006) Target-mediated drug disposition and dynamics. Biochem Pharmacol 72:1–10PubMedCrossRef

27.

Adams G, Schier R, McCall A, Simmons H, Horak E, Alpaugh K, Marks J, Weiner L (2001) High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res 61:4750–4755PubMed

28.

Ackerman ME, Chalouni C, Schmidt MM, Raman VV, Ritter G, Old LJ, Mellman I, Wittrup KD (2008) A33 antigen displays persistent surface expression. Cancer Immunol Immunother 57:1017–1027PubMedCrossRef

29.

Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, Akaike T, Maeda H (1998) Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res 89:307–314PubMed

30.

Sharkey RM, Natale A, Goldenberg DM, Mattes MJ (1991) Rapid blood clearance of immunoglobulin-G2A and immunoglobulin-G2B in nude-mice. Cancer Res 51:3102–3107PubMed

31.

Lonsmann H (1974) Interstitial fluid concentrations of albumin and immunoglobulin-G in normal men. Scand J Clin Lab Invest 34:119–122CrossRef

32.

Wiig H, Gyenge CC, Tenstad O (2005) The interstitial distribution of macromolecules in rat tumours is influenced by the negatively charged matrix components. J Physiol-London 567:557–567PubMedCrossRef

33.

Weis SM, Cheresh DA (2005) Pathophysiological consequences of VEGF-induced vascular permeability. Nature 437:497–504PubMedCrossRef

34.

Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK (1996) Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor vascular permeability factor antibody. Proc Natl Acad Sci USA 93:14765–14770PubMedCrossRef

35.

Maxwell JL, Terracio L, Borg TK, Baynes JW, Thorpe SR (1990) A fluorescent residualizing label for studies on protein-uptake and catabolism in vivo and in vitro. Biochem J 267:155–162PubMed

36.

Ferl GZ, Kenanova V, Wu AM, DiStefano JJ (2006) A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments. Mol Cancer Ther 5:1550–1558PubMedCrossRef

37.

Sung C, Youle RJ, Dedrick RL (1990) Pharmacokinetic analysis of immunotoxin uptake in solid tumors—role of plasma kinetics, capillary-permeability, and binding. Cancer Res 50:7382–7392PubMed

38.

Ahlstrom H, Christofferson R, Lorelius L (1988) Vascularization of the continuous human colonic cancer cell line LS 174 T deposited subcutaneously in nude rats. APMIS 96:701–710PubMedCrossRef

39.

Flynn A, Boxer G, Begent R, Pedley R (2001) Relationship between tumour morphology, antigen and antibody distribution measured by fusion of digital phosphor and photographic images. Cancer Immunol Immunother 50:77–81PubMedCrossRef

40.

Baxter L, Jain RK (1989) Transport of fluid and macromolecules in tumors: 1. Role of interstitial pressure and convection. Microvasc Res 37:77–104PubMedCrossRef

41.

Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM (2007) Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol 179:2815–2823PubMed

42.

Hilmas D, Gillette E (1974) Morphometric analyses of the microvasculature of tumors during growth and after X-irradiation. Cancer 33:103–110PubMedCrossRef

43.

Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, Ball H, Berek JS (1994) The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170(4):974–980, Mosby-Year Book IncPubMed

44.

Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM (2004) Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 22:701–706PubMedCrossRef

Title: Quantitating Antibody Uptake In Vivo: Conditional Dependence on Antigen Expression Levels
Authors: Greg M. Thurber
Ralph Weissleder
Publication date: 01-08-2011
Publisher: Springer-Verlag
Published in: Molecular Imaging and Biology / Issue 4/2011
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-010-0397-7

At a glance: The STEP trials

Springer Medicine

Quantitating Antibody Uptake In Vivo: Conditional Dependence on Antigen Expression Levels

Abstract

Purpose

Procedures

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Procedures

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2011

Tracking Long-Term Survival of Intramyocardially Delivered Human Adipose Tissue-Derived Stem Cells Using Bioluminescence Imaging

In Vitro Evaluation of Magnetic Resonance Imaging Contrast Agents for Labeling Human Liver Cells: Implications for Clinical Translation

Erratum to: Chronic Cannabinoid Administration to Periadolescent Rats Modulates the Metabolic Response to Acute Cocaine in the Adult Brain

In Vivo MRI Tracking of Cell Invasion and Migration in a Rat Glioma Model

A Low Molecular Weight Folate Receptor Targeted Contrast Agent for Magnetic Resonance Tumor Imaging

[11C]acetate PET/CT Visualizes Skeletal Muscle Exercise Participation, Impaired Function, and Recovery after Hip Arthroplasty; First Results